首页> 外文期刊>Clinical cardiology. >Beneficial Cardiometabolic Actions of Telmisartan Plus Amlodipine Therapy in Elderly Patients With Poorly Controlled Hypertension
【24h】

Beneficial Cardiometabolic Actions of Telmisartan Plus Amlodipine Therapy in Elderly Patients With Poorly Controlled Hypertension

机译:替米沙坦加氨氯地平治疗老年高血压不良患者的有益心脏代谢作用

获取原文
           

摘要

BackgroundThere is a growing body of evidence that blood pressure (BP) level is one of the major determinants of cardiovascular morbidity and mortality in individuals, including elderly people. However, to achieve a target BP level in the elderly is more difficult compared with patients aged 65 years. Current guidelines recommend combination drug therapy with different modes of action for the treatment of elderly patients with moderate hypertension (HT). However, the optimal combination regimen is not well established in elderly HT.HypothesisWe hypothesized that combination therapy of telmisartan plus amlodipine would exert favorable cardiometabolic actions in elderly HT.MethodsSeventeen elderly patients with essential HT who failed to achieve a target home BP level with treatment of 5 mg amlodipine plus 80 mg valsartan or 8 mg candesartan for at least 2 months were enrolled. Then the patients were assigned to replace their valsartan or candesartan with 40 mg telmisartan. The subjects were instructed to measure their own BP at home every day during the study periods.ResultsReplacement of valsartan or candesartan by telmisartan in amlodipine-treated elderly hypertensive patients showed a significant reduction in morning home systolic BP and evening home systolic and diastolic BP at 12 weeks. Switching to telmisartan significantly increased serum adiponectin level.ConclusionsOur present study suggests that combination therapy with telmisartan plus amlodipine may exert more beneficial cardiometabolic effects in elderly patients with HT compared with valsartan or candesartan plus amlodipine treatment. ? 2011 Wiley Periodicals, Inc.This work was supported in part by Grants of Collaboration with Venture Companies Project from the Ministry of Education, Culture, Sports, Science and Technology, Japan (to S.Y.). The authors have no other funding, financial relationships, or conflicts of interest to disclose.
机译:背景技术越来越多的证据表明,血压(BP)水平是包括老年人在内的个人心血管疾病发病率和死亡率的主要决定因素之一。但是,与<65岁的患者相比,要达到老年人的目标血压水平更加困难。当前的指南建议采用具有不同作用方式的联合药物疗法来治疗中度高血压(HT)的老年患者。假设我们假设替米沙坦联合氨氯地平联合治疗对老年人HT具有良好的心脏代谢作用。方法十七例老年HT患者在通过抗凝治疗后未能达到目标家庭血压水平参加了至少2个月的5毫克氨氯地平加80毫克缬沙坦或8毫克坎地沙坦。然后将患者分配为用40 mg替米沙坦代替缬沙坦或坎地沙坦。在研究期间,受试者每天都要在家中测量自己的血压。结果在氨氯地平治疗的老年高血压患者中,用替米沙坦替代缬沙坦或坎地沙坦的效果显着降低了早晨家用收缩压和晚上家用收缩压和舒张压周。切换至替米沙坦可显着提高血清脂联素水平。结论我们的研究表明,与缬沙坦或坎地沙坦加氨氯地平治疗相比,替米沙坦联合氨氯地平联合治疗对老年HT患者可产生更有益的心脏代谢作用。 ? 2011年Wiley Periodicals,Inc.这项工作部分得到了日本教育,文化,体育,科学和技术部(授予S.Y.)的Grants与风险企业合作项目的支持。作者没有其他资金,财务关系或利益冲突需要披露。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号